In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Risk Minimisation Activities: clarifications on Circular No. 635

Risk Minimisation Activities: clarifications on Circular No. 635

by In2Pharma | Feb 26, 2021 | News

Belgium Circular No. 635 (4 May 2018) details the approval procedure for risk minimisation activities (RMA). Certain paragraphs of this circular could be misinterpreted and specific situations were not considered. Therefore, the FAMHP provided more...

Recent Posts

  • Junior Consultant vacancy
  • Register your Industry Single Point of Contact (i-SPOC) on supply and availability
  • Update Commission Regulation regarding monacolins from red yeast rice
  • The FAMHP launches the Medicinal Product Management database
  • Request to marketing authorisation holders to send the approved version of the risk management plan

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België